NCT05877820View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Fumarate Hydratase Deficient Renal Cell Carcinoma
Interventions
BIOLOGICAL

Tislelizumab

Intravenous infusion

DRUG

Lenvatinib

Oral tablet

Trial Locations (1)

Unknown

RECRUITING

Ethics Committee of Shanghai Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER